Signifor Approval Highlights Success Of Novartis’ Parallel Development Strategy
Following its approval in Europe earlier in 2012, the FDA approval of Signifor for Cushing’s disease is just the latest piece of a strategy to bring the injectable to market in multiple indications, including acromegaly.
You may also be interested in...
The race to develop an easier-to-administer and less painful injection of octreotide for acromegaly is getting hotter, as Novartis takes over development of the Swedish company’s novel subcutaneous long-acting octreotide formulation.
Germany’s IQWiG has backed Novartis’ Jetrea for VMT, albeit with restricted indication, but knocked back Almirall’s Constella, citing study irrelevance.
A ruling by the EU’s Court of Justice overturning a previous decision by the European Commission on Laboratoire CTRS’s liver drug should make orphan drug applications more attractive in the region.